A Phase 2 interventional study of MK-2060 and Placebo in End-Stage Renal Disease, End-Stage Kidney Disease and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 120 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one has the largest enrollment, is the only one that started in 2021, is the only one in phase 2, and was the 7th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 506 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-2060 20 mg administered via IV infusion during dialysis as a loading dose: QOD during week 1 (3 administrations), then QW after week 1
Drug: MK-2060
MK-2060 6 mg administered via intravenous (IV) infusion during dialysis as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1
Drug: MK-2060
Placebo (normal saline) administered via IV infusion during dialysis as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1
Drug: Placebo
MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
Normal saline administered via IV infusion
Time to First Arteriovenous Graft (AVG) Thrombosis Event
An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent clinical adjudication committee (CAC) adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.
Time frame: From date of randomization until the date of first occurrence of an AVG thrombosis event, assessed up to approximately 37 months
Time to Each AVG Thrombosis Event (First and Recurrent)
An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent CAC adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.
Time frame: Up to approximately 37 months
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with one or more AEs is presented.
Time frame: Up to approximately 40 months
Time to First Event of International Society on Thrombosis (ISTH) Major Bleeding Event or a Clinically Relevant Non-Major Bleeding Event
Major bleeding events were defined as a having symptomatic presentation and including ≥1 of the following criteria: 1) Fatal bleeding 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome 3) Bleeding causing decrease in hematocrit level of 20 g/L or more or leading to transfusion of ≥2 units of whole blood or red cells. Clinically relevant non-major bleeding events were defined as signs or symptoms of hemorrhage that do not meet criteria for major bleeding events but meet ≥1 of the following criteria: 1) Requiring medical intervention by healthcare professional 2) Leading to hospitalization or increased level of care 3) Prompting face-to-face evaluation by healthcare professional. A time-to-event methodology was used. The incidence rate is presented.
Time frame: From date of first dose of study intervention until the first ISTH major bleeding event or a clinically relevant non-major bleeding event. assessed up to approximately 40 months
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.
Time frame: Up to approximately 37 months
| Milestone | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Started | 171 | 167 | 168 |
| Treated | 170 | 164 | 168 |
| Completed | 105 | 113 | 113 |
| Not completed | 66 | 54 | 55 |
| Withdrew: Death | 47 | 42 | 39 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 3 | 0 | 2 |
| Withdrew: Withdrawal by subject | 13 | 8 | 10 |
| Withdrew: Lost to follow-up | 2 | 4 | 3 |
| Withdrew: Status not recorded | 0 | 0 | 1 |
An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent clinical adjudication committee (CAC) adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.
| events per 100 person-years | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Time to First Arteriovenous Graft (AVG) Thrombosis Event | 23.80 | 22.98 | 30.17 |
An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent CAC adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.
| events per 100 person-years | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Time to Each AVG Thrombosis Event (First and Recurrent) | 38.95 | 37.85 | 42.97 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with one or more AEs is presented.
| Participants | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Experience One or More Adverse Events (AEs) | 161 | 143 | 155 |
Major bleeding events were defined as a having symptomatic presentation and including ≥1 of the following criteria: 1) Fatal bleeding 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome 3) Bleeding causing decrease in hematocrit level of 20 g/L or more or leading to transfusion of ≥2 units of whole blood or red cells. Clinically relevant non-major bleeding events were defined as signs or symptoms of hemorrhage that do not meet criteria for major bleeding events but meet ≥1 of the following criteria: 1) Requiring medical intervention by healthcare professional 2) Leading to hospitalization or increased level of care 3) Prompting face-to-face evaluation by healthcare professional. A time-to-event methodology was used. The incidence rate is presented.
| events per 100 person-years | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Time to First Event of International Society on Thrombosis (ISTH) Major Bleeding Event or a Clinically Relevant Non-Major Bleeding Event | 24.73 | 18.05 | 14.04 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.
| Participants | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Discontinue Study Intervention Due to an AE | 47 | 32 | 46 |
Collected over Up to approximately 40 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-2060 20 mg | 50/171 (29.2%) | 110/170 (64.7%) | 111/170 (65.3%) |
| MK-2060 6 mg | 43/167 (25.7%) | 95/164 (57.9%) | 106/164 (64.6%) |
| Placebo | 41/168 (24.4%) | 112/168 (66.7%) | 109/168 (64.9%) |
| Event | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Arteriovenous graft thrombosisInjury, poisoning and procedural complications | 13/170 | 19/164 | 19/168 |
| PneumoniaInfections and infestations | 10/170 | 9/164 | 13/168 |
| HyperkalaemiaMetabolism and nutrition disorders | 7/170 | 6/164 | 12/168 |
| SepsisInfections and infestations | 7/170 | 4/164 | 11/168 |
| HypervolaemiaMetabolism and nutrition disorders | 8/170 | 9/164 | 11/168 |
| Cardiac failure congestiveCardiac disorders | 10/170 | 1/164 | 5/168 |
| Chest painGeneral disorders | 3/170 | 9/164 | 2/168 |
| Acute myocardial infarctionCardiac disorders | 9/170 | 6/164 | 8/168 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 6/170 | 8/164 | 5/168 |
| COVID-19Infections and infestations | 7/170 | 3/164 | 6/168 |
| Event | MK-2060 20 mg | MK-2060 6 mg | Placebo |
|---|---|---|---|
| Arteriovenous graft thrombosisInjury, poisoning and procedural complications | 29/170 | 35/164 | 43/168 |
| Arteriovenous graft site stenosisInjury, poisoning and procedural complications | 22/170 | 23/164 | 23/168 |
| DiarrhoeaGastrointestinal disorders | 11/170 | 20/164 | 9/168 |
| COVID-19Infections and infestations | 13/170 | 10/164 | 18/168 |
| HypertensionVascular disorders | 17/170 | 9/164 | 10/168 |
| Arteriovenous graft site haemorrhageInjury, poisoning and procedural complications | 9/170 | 16/164 | 7/168 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/170 | 8/164 | 16/168 |
| HypotensionVascular disorders | 12/170 | 7/164 | 15/168 |
| FallInjury, poisoning and procedural complications | 15/170 | 11/164 | 9/168 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 15/170 | 6/164 | 9/168 |
| Age, Continuous(Years) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 13.5 | 58.8 ± 12.8 | 60.5 ± 14.8 | 60.5 ± 13.8 |
| Sex: Female, Male(Participants) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 97 | 81 | 83 | 261 |
| Male | 74 | 86 | 85 | 245 |
| Ethnicity (NIH/OMB)(Participants) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 77 | 67 | 65 | 209 |
| Not Hispanic or Latino | 91 | 98 | 100 | 289 |
| Unknown or Not Reported | 3 | 2 | 3 | 8 |
| Race (NIH/OMB)(Participants) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 1 | 4 |
| Asian | 6 | 6 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 2 |
| Black or African American | 63 | 73 | 67 | 203 |
| White | 99 | 86 | 94 | 279 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region(Participants) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| US | 118 | 117 | 118 | 353 |
| non-US | 53 | 50 | 50 | 153 |
| Previous Thrombosis of Active Arteriovenous Graft (AVG)(Participants) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| Yes | 38 | 35 | 40 | 113 |
| No | 133 | 132 | 128 | 393 |
| Regular Aspirin Use up to 150 mg Daily at Baseline(Participants) | MK-2060 20 mg | MK-2060 6 mg | Placebo | Total |
|---|---|---|---|---|
| Yes | 72 | 69 | 67 | 208 |
| No | 99 | 98 | 101 | 298 |
Showing the first 100 of 120 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2021 to primary completion in Oct 2024, 37 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 37 months is above that.
Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-2060